Diagnostic accuracy of SSR-PET/CT compared to histopathology in the identification of liver metastases from well-differentiated neuroendocrine tumors.
Liver metastases
MRI
NET
PET/CT
SSR
Journal
Cancer imaging : the official publication of the International Cancer Imaging Society
ISSN: 1470-7330
Titre abrégé: Cancer Imaging
Pays: England
ID NLM: 101172931
Informations de publication
Date de publication:
28 Sep 2023
28 Sep 2023
Historique:
received:
03
07
2023
accepted:
19
09
2023
medline:
2
10
2023
pubmed:
29
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Histopathology is the reference standard for diagnosing liver metastases of neuroendocrine tumors (NETs). Somatostatin receptor-positron emission tomography / computed tomography (SSR-PET/CT) has emerged as a promising non-invasive imaging modality for staging NETs. We aimed to assess the diagnostic accuracy of SSR-PET/CT in the identification of liver metastases in patients with proven NETs compared to histopathology. Histopathologic reports of 139 resected or biopsied liver lesions of patients with known NET were correlated with matching SSR-PET/CTs and the positive/negative predictive value (PPV/NPV), sensitivity, specificity, and diagnostic accuracy of SSR-PET/CT were evaluated. PET/CT reading was performed by one expert reader blinded to histopathology and clinical data. 133 of 139 (95.7%) liver lesions showed malignant SSR-uptake in PET/CT while initial histopathology reported on 'liver metastases of NET´ in 127 (91.4%) cases, giving a PPV of 91.0%. Re-biopsy of the initially histopathologically negative lesions (reference standard) nevertheless diagnosed 'liver metastases of NET' in 6 cases, improving the PPV of PET/CT to 95.5%. Reasons for initial false-negative histopathology were inadequate sampling in the sense of non-target biopsies. The 6 (4.3%) SSR-negative lesions were all G2 NETs with a Ki-67 between 2-15%. SSR-PET/CT is a highly accurate imaging modality for the diagnosis of liver metastases in patients with proven NETs. However, we found that due to the well-known tumor heterogeneity of NETs, specifically in G2 NETs approximately 4-5% are SSR-negative and may require additional imaging with [
Sections du résumé
BACKGROUND
BACKGROUND
Histopathology is the reference standard for diagnosing liver metastases of neuroendocrine tumors (NETs). Somatostatin receptor-positron emission tomography / computed tomography (SSR-PET/CT) has emerged as a promising non-invasive imaging modality for staging NETs. We aimed to assess the diagnostic accuracy of SSR-PET/CT in the identification of liver metastases in patients with proven NETs compared to histopathology.
METHODS
METHODS
Histopathologic reports of 139 resected or biopsied liver lesions of patients with known NET were correlated with matching SSR-PET/CTs and the positive/negative predictive value (PPV/NPV), sensitivity, specificity, and diagnostic accuracy of SSR-PET/CT were evaluated. PET/CT reading was performed by one expert reader blinded to histopathology and clinical data.
RESULTS
RESULTS
133 of 139 (95.7%) liver lesions showed malignant SSR-uptake in PET/CT while initial histopathology reported on 'liver metastases of NET´ in 127 (91.4%) cases, giving a PPV of 91.0%. Re-biopsy of the initially histopathologically negative lesions (reference standard) nevertheless diagnosed 'liver metastases of NET' in 6 cases, improving the PPV of PET/CT to 95.5%. Reasons for initial false-negative histopathology were inadequate sampling in the sense of non-target biopsies. The 6 (4.3%) SSR-negative lesions were all G2 NETs with a Ki-67 between 2-15%.
CONCLUSION
CONCLUSIONS
SSR-PET/CT is a highly accurate imaging modality for the diagnosis of liver metastases in patients with proven NETs. However, we found that due to the well-known tumor heterogeneity of NETs, specifically in G2 NETs approximately 4-5% are SSR-negative and may require additional imaging with [
Identifiants
pubmed: 37770958
doi: 10.1186/s40644-023-00614-2
pii: 10.1186/s40644-023-00614-2
pmc: PMC10537814
doi:
Substances chimiques
Receptors, Somatostatin
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Radiopharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
92Informations de copyright
© 2023. International Cancer Imaging Society (ICIS).
Références
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
Eur J Cancer. 2023 Jun;186:122-132
pubmed: 37062210
J Nucl Med. 2016 Jan;57(1):34-40
pubmed: 26471695
Eur J Nucl Med Mol Imaging. 2012 Aug;39(8):1271-7
pubmed: 22526963
EJNMMI Res. 2022 May 7;12(1):28
pubmed: 35524900
Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1659-68
pubmed: 21626438
Br J Cancer. 2023 Feb;128(4):549-555
pubmed: 36434154
J Nucl Med. 2017 Nov;58(11):1718-1726
pubmed: 28818983
CMAJ. 2017 Mar 13;189(10):E398-E404
pubmed: 28385820
Theranostics. 2017 Mar 1;7(5):1149-1158
pubmed: 28435454
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4182-4193
pubmed: 35674739
Cancers (Basel). 2023 Mar 20;15(6):
pubmed: 36980746
J Clin Oncol. 2009 Oct 1;27(28):4656-63
pubmed: 19704057
J Cancer Res Clin Oncol. 2022 Jan;148(1):225-236
pubmed: 34110489
J Nucl Med. 2012 Nov;53(11):1686-92
pubmed: 22984220
Contrast Media Mol Imaging. 2018 Feb 26;2018:2340389
pubmed: 29681780
J Nucl Med. 2013 Oct;54(10):1755-9
pubmed: 23929824
Endocr Relat Cancer. 2005 Dec;12(4):1083-92
pubmed: 16322345
Cancer Imaging. 2023 Apr 25;23(1):41
pubmed: 37098632
Am J Surg Pathol. 2011 Jun;35(6):853-60
pubmed: 21566513
Abdom Imaging. 2012 Dec;37(6):1004-20
pubmed: 22422069
J Nucl Med. 2011 Dec;52(12):1864-70
pubmed: 22072704
J Natl Compr Canc Netw. 2012 Jun 1;10(6):724-64
pubmed: 22679117
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1585-92
pubmed: 26922350